Trial Profile
A Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF a Chimeric Monoclonal Antibody (Infliximab, REMICADE) in Pediatric Subjects With Moderate to Severe CROHN'S Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jul 2023
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms REACH
- Sponsors Centocor
- 23 May 2021 Results of post-hoc analysis comparing performance of the sPCDAI and full PCDAI in 2 pediatric Crohns disease trials: UNISTAR and REACH presented at the Digestive Disease Week 2021
- 05 Nov 2010 New trial record.